henan lingrui pharmaceutical announced that the company recently received the approval of the National Medical Products Administration to issue the Drug Registration Certificate for Mometasone Cream. This pharmaceutical is a cream formulation with a concentration of 2%, developed by GlaxoSmithKline, suitable for skin infections caused by Gram-positive bacteria. In 2023, the sales revenue of Mometasone Cream at national retail terminals amounted to 0.918 billion RMB. As of now, the company has accumulated approximately 8.1083 million RMB in research and development investment. Obtaining this drug registration certificate will enrich the company's product line, enhance market competitiveness, and is expected to have a positive impact on the company's operation.